Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRR7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $78,961
Award facts
- Contract value 100% obligated
- $78,961.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $78,961 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The award was issued on December 29, 2025, with an ultimate completion date of January 21, 2026, and carries no set-aside designation, indicating the contractor competed in an unrestricted procurement. DMS Pharmaceutical Group will perform the work at its Park Ridge location and will serve as the sole prime contractor with no identified subcontractors on this delivery order.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.99 billion acquisition strategy established to support recurring pharmaceutical supply needs across Department of Defense military healthcare facilities worldwide. The IDC, designated contract SPE2DR and awarded November 13, 2025, positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors authorized to provide comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables through firm fixed-price delivery orders through December 31, 2036. This specific delivery order for XOLAIR, an immunosuppressant biologic agent, demonstrates the contractor's role in supplying specialized pharmaceutical products to support DoD healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FCRR7?
SPE2DR26FCRR7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26FCRR7 worth?
The government has obligated $78,961 on SPE2DR26FCRR7.
Is contract SPE2DR26FCRR7 an order under another contract?
Yes. SPE2DR26FCRR7 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRR7 competed?
The extent of competition for SPE2DR26FCRR7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award